Cytotoxic Conjugates with Self-Immolative Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cytotoxic compounds used in cancer chemotherapy often exhibit high toxicity and instability in plasma, limiting their application due to acute and chronic side effects, and their stability is compromised when functional groups are added to enhance stability, leading to reduced therapeutic activity.
Innovation Solution
Development of cytotoxic compounds with self-immolative linkers that form conjugates with cleavable substrates, allowing for selective delivery and activation at the site of action through enzymatic cleavage, reducing toxicity and improving stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If functional groups are added to stabilize cytotoxic compounds in plasma, then stability is improved, but therapeutic activity is reduced
Solution Approach 1:
The cytotoxic compound is segmented into two parts: a stable conjugate form for plasma circulation and an active form for therapeutic action. The conjugate contains a cleavable linker that separates the cytotoxic agent from stabilizing groups, allowing the stable form to circulate in plasma while the active form exerts therapeutic effect after linker cleavage by intracellular enzymes
Solution Approach 2:
A cleavable linker serves as an intermediary between the cytotoxic compound and stabilizing functional groups. This linker remains intact during plasma circulation, maintaining stability, but is cleaved by intracellular enzymes (such as esterases or proteases) to release the active cytotoxic agent, thus mediating the transition from stable to active form
2Reliability
If high doses of cytotoxic compounds are administered to achieve therapeutic effect, then antitumor activity is improved, but toxicity to normal tissues increases
Solution Approach 1:
The conjugate system exhibits local quality by having different properties in different locations: in plasma, the conjugate form provides stability and reduced toxicity, while upon cellular uptake and enzyme-mediated cleavage, the active cytotoxic form is released locally at the target site to exert maximum antitumor effect, thus achieving location-dependent functionality
Solution Approach 2:
The cleavable linker, which could be seen as a vulnerability point, is converted into a beneficial feature by utilizing intracellular enzymes to trigger activation. The same enzymatic systems that exist in all cells become the key to selective activation, and the conjugate design ensures that activation occurs preferentially in tumor cells due to their unique enzymatic environment or uptake characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cytotoxic compounds can be delivered in an inactive form and activated at the tumor site, minimizing side effects and maintaining therapeutic efficacy while enhancing stability, thus offering a more targeted and effective treatment for cancer.
Implementation Method 1
The conjugates can be used to form prodrugs as other diagnostic and therapeutic moieties... can be cleaved in vivo... enzymatic methods in vivo, releasing an active drug moiety from the prodrug derivative
Data Source
AI summary
The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.